Gilead’s experimental COVID-19 drug shows promise but analysts remain cautious

Analysts say early data showing Gilead Sciences Inc.’s remdesivir improved clinical outcomes for two-thirds of a small group of severely ill COVID-19 patients is promising but they caution against viewing the experimental drug as a silver bullet in the fight against the novel coronavirus.